Some of the current examples of approved biomarkers for diagnosis are prostate-specific antigen (PSA) in prostate cancer or human epidermal growth factor receptor 2 (HER2) in breast cancer, in this latter case, being itself the target for therapeutic actions [31,32]. This evidence concerns the gene ERBB2 and prostate cancer.